Avid prepares to present findings of Alzheimer's study

06/23/2010 | New York Times (tiered subscription model), The

Avid Radiopharmaceuticals, a company that developed fluoride 18-based dyes for use in PET scans of amyloid plaques, said it has received the results of a study using its dye to determine whether Alzheimer's disease diagnosed through a PET scan correlates with that determined through a brain autopsy. The results, to be presented at the Alzheimer's Association meeting next month, will "have a big impact on Alzheimer's disease," said Dr. Daniel Skovronsky, founder of the company.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA